Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Naïve Subjects With Metastatic Non-Small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Progression-free survival (PFS) rate
week 18
No
United States: Food and Drug Administration
CS7017-A-U202
NCT00806286
December 2008
August 2012
Name | Location |
---|---|
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Eastern Virginia Medical School | Norfolk, Virginia 23507 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
Michiana Hematology-Oncology | South Bend, Indiana 46601 |
Harbor View Cancer Center | Baltimore, Maryland 21225 |
Southern Illinois Hematology/Oncology | Centralia, Illinois 62801 |
Signal Point Clinical Research Center | Middletown, Ohio 45042 |
University Colorado Cancer Center | Aurora, Colorado 80045 |
Georgetown Univ. Medical Center | Washington, District of Columbia 20007 |
Penn State Milton Hershey Cancer Center | Hershey, Pennsylvania 17033 |